Transaction DateRecipientSharesTypePriceValue
9th September 2020Group, Llc Redmile8,650Open or private purchase$51.85$448,523.26
9th September 2020Group, Llc Redmile14,610Open or private purchase$52.96$773,811.35
8th September 2020Bros. Advisors Lp Baker6,151Open or private purchase$47.39$291,479.90
8th September 2020Bros. Advisors Lp Baker15,172Open or private purchase$47.47$720,199.67
8th September 2020Bros. Advisors Lp Baker15,807Open or private purchase$47.04$743,482.25
8th September 2020Bros. Advisors Lp Baker76,473Open or private purchase$47.39$3,623,856.64
8th September 2020Bros. Advisors Lp Baker1,220Open or private purchase$47.47$57,912.18
8th September 2020Bros. Advisors Lp Baker185Open or private purchase$45.88$8,486.88
8th September 2020Group, Llc Redmile47,113Open or private purchase$49.91$2,351,504.06
8th September 2020Bros. Advisors Lp Baker1,272Open or private purchase$47.04$59,828.52
Atreca
Atreca logo

Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients.

Ticker: BCEL
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1532346
Employees: 113
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals